Zamani Noushin, Ganjy Zeinab, Sharif Mohammad Reza, Taghavi Ardakani Abbas, Kheirkhah Davood, Sayyah Mansour, Azimi Ali, Sharif Alireza
Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Clinical Research Development Unit, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Evid Based Complement Alternat Med. 2022 Aug 22;2022:2541117. doi: 10.1155/2022/2541117. eCollection 2022.
Increased levels of inflammatory cytokines and oxidative damage may play crucial roles in the pathogenesis of brucellosis. The purpose of this trial was to evaluate the impact of probiotics administration on clinical status and biomarkers of oxidative damage and inflammation in pediatric patients diagnosed with brucellosis.
This randomized, double-blind, and placebo-controlled trial was performed by recruiting 40 patients, 8-15 years of age, who had been diagnosed with brucellosis. Study participants were randomly allocated into two groups to receive either probiotics supplement or placebo ( = 20 each group) for 8 weeks. Blood samples were collected at the onset and after 8 weeks of intervention to quantify biochemical parameters. Clinical status was examined by a pediatric infectious disease specialist.
Following 8-week intervention, probiotics supplementation substantially improved total antioxidant capacity ( < 0.001) and malondialdehyde (=0.002). Furthermore, the difference between probiotics group and placebo group for the duration of fever (=0.02) and musculoskeletal pain (=0.001) was statistically significant, though probiotics administration had no significant effects on high-sensitivity C-reactive protein, total glutathione, and other clinical outcomes compared with placebo.
Overall, probiotics intake had beneficial impact on clinical status and body antioxidative defense system in pediatric patients with brucellosis.
炎症细胞因子水平升高和氧化损伤可能在布鲁氏菌病的发病机制中起关键作用。本试验的目的是评估给予益生菌对诊断为布鲁氏菌病的儿科患者的临床状况以及氧化损伤和炎症生物标志物的影响。
本随机、双盲、安慰剂对照试验招募了40名8至15岁被诊断为布鲁氏菌病的患者。研究参与者被随机分为两组，分别接受益生菌补充剂或安慰剂（每组20人），为期8周。在干预开始时和干预8周后采集血样以量化生化参数。由儿科传染病专家检查临床状况。
经过8周的干预，补充益生菌显著提高了总抗氧化能力（<0.001）和丙二醛（=0.002）。此外，益生菌组和安慰剂组在发热持续时间（=0.02）和肌肉骨骼疼痛（=0.001）方面的差异具有统计学意义，不过与安慰剂相比，给予益生菌对高敏C反应蛋白、总谷胱甘肽和其他临床结果没有显著影响。
总体而言，摄入益生菌对患有布鲁氏菌病的儿科患者的临床状况和身体抗氧化防御系统有有益影响。
